Multicenter study of QuantiFERON®-TB Gold Plus in patients with active tuberculosis

D. J. Horne, B. E. Jones, A. Kamada, K. Fukushima, Kevin Winthrop, S. A.R. Siegel, A. Kovacs, P. Anthony, K. A. Meekin, S. Bhat, P. Kerndt, A. Chang, D. M. Koelle, M. Narita

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Setting: QuantiFERONw-TB Gold Plus (QFT-Plus), recently approved for use in the United States, is a newgeneration QuantiFERON assay that differs from its predecessors in that it uses an additional antigen tube containing peptides to elicit both CD8+ and CD4+ Tlymphocyte responses. Objective : To assess the sensitivity of QFT-Plus compared with QuantiFERON®-TB Gold In-Tube (QFT-GIT) in participants with active TB. Design: Adult patients with active TB at three US and two Japanese sites were eligible for this study if they had culture-confirmed TB and were either untreated or had received ≤14 days of anti-tuberculosis treatment. Results : We enrolled 164 participants, nine of whom had indeterminate results. Excluding indeterminate values, there were 150 QFT-GIT-positive results among 159 tests and 146 QFT-Plus-positive results among 157 tests, with sensitivities of respectively 94.3% (95%CI 89.5-97.4) and 93.02% (95%CI 87.8-96.5%). The estimated sensitivities for the two tests were not significantly different (P=0.16). Overall test agreement was 98.7%, with a κ statistic of 0.89 (95%CI 0.75-1.00). Conclusion: In this multisite study, we found that QFT-Plus had similar sensitivity to QFT-GIT in adult patients with active TB.

Original languageEnglish (US)
Pages (from-to)617-621
Number of pages5
JournalInternational Journal of Tuberculosis and Lung Disease
Volume22
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Gold
Multicenter Studies
Tuberculosis
Antigens
Peptides

Keywords

  • Diagnosis
  • Epidemiology
  • Latent tuberculous infection
  • Test discordance

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Multicenter study of QuantiFERON®-TB Gold Plus in patients with active tuberculosis. / Horne, D. J.; Jones, B. E.; Kamada, A.; Fukushima, K.; Winthrop, Kevin; Siegel, S. A.R.; Kovacs, A.; Anthony, P.; Meekin, K. A.; Bhat, S.; Kerndt, P.; Chang, A.; Koelle, D. M.; Narita, M.

In: International Journal of Tuberculosis and Lung Disease, Vol. 22, No. 6, 01.06.2018, p. 617-621.

Research output: Contribution to journalArticle

Horne, DJ, Jones, BE, Kamada, A, Fukushima, K, Winthrop, K, Siegel, SAR, Kovacs, A, Anthony, P, Meekin, KA, Bhat, S, Kerndt, P, Chang, A, Koelle, DM & Narita, M 2018, 'Multicenter study of QuantiFERON®-TB Gold Plus in patients with active tuberculosis', International Journal of Tuberculosis and Lung Disease, vol. 22, no. 6, pp. 617-621. https://doi.org/10.5588/ijtld.17.0721
Horne, D. J. ; Jones, B. E. ; Kamada, A. ; Fukushima, K. ; Winthrop, Kevin ; Siegel, S. A.R. ; Kovacs, A. ; Anthony, P. ; Meekin, K. A. ; Bhat, S. ; Kerndt, P. ; Chang, A. ; Koelle, D. M. ; Narita, M. / Multicenter study of QuantiFERON®-TB Gold Plus in patients with active tuberculosis. In: International Journal of Tuberculosis and Lung Disease. 2018 ; Vol. 22, No. 6. pp. 617-621.
@article{deb605e2d5314e8091a0ba8bc6907938,
title = "Multicenter study of QuantiFERON{\circledR}-TB Gold Plus in patients with active tuberculosis",
abstract = "Setting: QuantiFERONw-TB Gold Plus (QFT-Plus), recently approved for use in the United States, is a newgeneration QuantiFERON assay that differs from its predecessors in that it uses an additional antigen tube containing peptides to elicit both CD8+ and CD4+ Tlymphocyte responses. Objective : To assess the sensitivity of QFT-Plus compared with QuantiFERON{\circledR}-TB Gold In-Tube (QFT-GIT) in participants with active TB. Design: Adult patients with active TB at three US and two Japanese sites were eligible for this study if they had culture-confirmed TB and were either untreated or had received ≤14 days of anti-tuberculosis treatment. Results : We enrolled 164 participants, nine of whom had indeterminate results. Excluding indeterminate values, there were 150 QFT-GIT-positive results among 159 tests and 146 QFT-Plus-positive results among 157 tests, with sensitivities of respectively 94.3{\%} (95{\%}CI 89.5-97.4) and 93.02{\%} (95{\%}CI 87.8-96.5{\%}). The estimated sensitivities for the two tests were not significantly different (P=0.16). Overall test agreement was 98.7{\%}, with a κ statistic of 0.89 (95{\%}CI 0.75-1.00). Conclusion: In this multisite study, we found that QFT-Plus had similar sensitivity to QFT-GIT in adult patients with active TB.",
keywords = "Diagnosis, Epidemiology, Latent tuberculous infection, Test discordance",
author = "Horne, {D. J.} and Jones, {B. E.} and A. Kamada and K. Fukushima and Kevin Winthrop and Siegel, {S. A.R.} and A. Kovacs and P. Anthony and Meekin, {K. A.} and S. Bhat and P. Kerndt and A. Chang and Koelle, {D. M.} and M. Narita",
year = "2018",
month = "6",
day = "1",
doi = "10.5588/ijtld.17.0721",
language = "English (US)",
volume = "22",
pages = "617--621",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "6",

}

TY - JOUR

T1 - Multicenter study of QuantiFERON®-TB Gold Plus in patients with active tuberculosis

AU - Horne, D. J.

AU - Jones, B. E.

AU - Kamada, A.

AU - Fukushima, K.

AU - Winthrop, Kevin

AU - Siegel, S. A.R.

AU - Kovacs, A.

AU - Anthony, P.

AU - Meekin, K. A.

AU - Bhat, S.

AU - Kerndt, P.

AU - Chang, A.

AU - Koelle, D. M.

AU - Narita, M.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Setting: QuantiFERONw-TB Gold Plus (QFT-Plus), recently approved for use in the United States, is a newgeneration QuantiFERON assay that differs from its predecessors in that it uses an additional antigen tube containing peptides to elicit both CD8+ and CD4+ Tlymphocyte responses. Objective : To assess the sensitivity of QFT-Plus compared with QuantiFERON®-TB Gold In-Tube (QFT-GIT) in participants with active TB. Design: Adult patients with active TB at three US and two Japanese sites were eligible for this study if they had culture-confirmed TB and were either untreated or had received ≤14 days of anti-tuberculosis treatment. Results : We enrolled 164 participants, nine of whom had indeterminate results. Excluding indeterminate values, there were 150 QFT-GIT-positive results among 159 tests and 146 QFT-Plus-positive results among 157 tests, with sensitivities of respectively 94.3% (95%CI 89.5-97.4) and 93.02% (95%CI 87.8-96.5%). The estimated sensitivities for the two tests were not significantly different (P=0.16). Overall test agreement was 98.7%, with a κ statistic of 0.89 (95%CI 0.75-1.00). Conclusion: In this multisite study, we found that QFT-Plus had similar sensitivity to QFT-GIT in adult patients with active TB.

AB - Setting: QuantiFERONw-TB Gold Plus (QFT-Plus), recently approved for use in the United States, is a newgeneration QuantiFERON assay that differs from its predecessors in that it uses an additional antigen tube containing peptides to elicit both CD8+ and CD4+ Tlymphocyte responses. Objective : To assess the sensitivity of QFT-Plus compared with QuantiFERON®-TB Gold In-Tube (QFT-GIT) in participants with active TB. Design: Adult patients with active TB at three US and two Japanese sites were eligible for this study if they had culture-confirmed TB and were either untreated or had received ≤14 days of anti-tuberculosis treatment. Results : We enrolled 164 participants, nine of whom had indeterminate results. Excluding indeterminate values, there were 150 QFT-GIT-positive results among 159 tests and 146 QFT-Plus-positive results among 157 tests, with sensitivities of respectively 94.3% (95%CI 89.5-97.4) and 93.02% (95%CI 87.8-96.5%). The estimated sensitivities for the two tests were not significantly different (P=0.16). Overall test agreement was 98.7%, with a κ statistic of 0.89 (95%CI 0.75-1.00). Conclusion: In this multisite study, we found that QFT-Plus had similar sensitivity to QFT-GIT in adult patients with active TB.

KW - Diagnosis

KW - Epidemiology

KW - Latent tuberculous infection

KW - Test discordance

UR - http://www.scopus.com/inward/record.url?scp=85046951256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046951256&partnerID=8YFLogxK

U2 - 10.5588/ijtld.17.0721

DO - 10.5588/ijtld.17.0721

M3 - Article

C2 - 29862944

AN - SCOPUS:85046951256

VL - 22

SP - 617

EP - 621

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 6

ER -